Market Capitalization

Fermi America's board defeats an ousted founder's legal challenge as the company races to build a massive 17 GW private energy grid for hyperscale AI.

Wetour Robotics is pivoting from wearable tech to heavy electrical transformers. Can a $3M startup solve the massive Texas data center power bottleneck?

VinFast is expanding its U.S. dealership network and CPO program. But with ongoing lawsuits, recalls, and supply chain woes, is this pivot enough?

Myseum.AI's new print partnership with Fujifilm reveals the hidden economic and technical hurdles of building a truly privacy-first digital ecosystem in 2026.

Delixy Holdings aims to pivot from oil trading to upstream production in a complex Kazakh energy deal, but regulatory and financial hurdles loom large.

Amid economic headwinds, Western Pacific Trust's dividend shines. We analyze how its niche focus on private capital markets creates resilient value.

Facing Nasdaq delisting, Israeli tech firm HUB Cyber Security executes a 1-for-25 reverse split. Is it a lifeline or a sign of deeper trouble?

Forward Water Technologies secured $535k in high-interest debt, a risky but vital move. We analyze if this costly capital can propel its green tech to market.

Beyond the crypto hype, stablecoins are maturing into critical infrastructure. As Singapore hosts the Stablecoin Summit, a look at how regulation is paving the way for a trillion-dollar market.

As Aktis Oncology presents at key investor conferences, it showcases a precision miniprotein platform and a major Eli Lilly deal in a booming market.

With Phase 3 data imminent and a new Nasdaq ticker, Helus Pharma is using a key investor conference to frame its novel therapies as the next frontier.

As Vertical Aerospace courts investors, its hybrid and defense pivots will be tested. Can it secure the capital needed to clear the runway to certification?

With a second multimillion-dollar deal from a tech giant, Orion Energy Systems proves that efficiency and a solid supply chain are key to the AI build-out.

Spirit Blockchain Capital rebrands as Impauer Technologies, shedding its crypto-specific identity. Is this a visionary pivot or a desperate escape from a volatile market?

A major automaker's quiet bet on Hirain and Arbe's radar for Level 3 driving is more than a press release. It's a lesson in execution over rhetoric.

The Israeli biotech firm gained crucial FDA feedback for its personalized therapy, NewRal. But in a field laden with failure, is this a true breakthrough?

TOYO Co., Ltd. is betting its future on controlling the entire solar supply chain. As its CSO meets investors, can this bold strategy navigate trade risks?

Granted a 180-day Nasdaq extension, AI infrastructure firm Alpha Compute must now prove its high-tech vision is more than a penny stock reality.

Samsung Biologics is raising KRW 3 trillion to buy a peptide specialist and build a mega-campus. It's a bold play that trades short-term dilution for long-term dominance.

GRI Bio showcases its promising IPF drug, GRI-0621, in a new webcast, aiming to capture investor and scientific attention before a key industry congress.